RCT | Omecamtiv Mecarbil does not improve exercise capacity in chronic heart failure with reduced ejection fraction.

Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Author Interview: Can Omecamtiv Mecarbil Improve Peak Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)? – JAMA

Commentaries:

Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF – Medscape (free registration required)

Omecamtiv mecarbil not associated with improved exercise capacity compared with placebo in patients with chronic heart failure with reduced ejection fraction – Physician’s Weekly

Related: #AHA20 – Randomized trial: In patients with systolic heart failure, Cardiac Myosin activation with Omecamtiv Mecarbil led to modest reduction in heart failure events

Commentary on Twitter

#OriginalInvestigation: Multicenter randomized clinical trial found that, in patients with chronic #HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. @GLewisCardiol https://t.co/f27Y0oya6S

— JAMA (@JAMA_current) July 20, 2022